Century Therapeutics, Inc.
Century Therapeutics, Inc. (IPSC) Revenue
Annual & quarterly revenue history · segment & region breakdown
IPSC · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCentury Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 1556.76% year-over-year from $0.11B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.11B | +$0.10B | +1556.76% |
| 2024-12-31 | $0.01B | +$0.00B | +194.81% |
| 2023-12-31 | $0.00B | -$0.00B | -57.01% |
| 2022-12-31 | $0.01B | +$0.01B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Century Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Century Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Century Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IPSC revenue · 4 questionsIPSC's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 1556.76% year-over-year from $0.11B in FY2025.
▸ Source: FMP · Century Therapeutics, Inc. SEC filings · GAAP · Century Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026